M.H. Cullen

3.7k total citations
61 papers, 2.6k citations indexed

About

M.H. Cullen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, M.H. Cullen has authored 61 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 23 papers in Oncology and 20 papers in Surgery. Recurrent topics in M.H. Cullen's work include Lung Cancer Treatments and Mutations (19 papers), Testicular diseases and treatments (13 papers) and Lung Cancer Research Studies (12 papers). M.H. Cullen is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Testicular diseases and treatments (13 papers) and Lung Cancer Research Studies (12 papers). M.H. Cullen collaborates with scholars based in United Kingdom, United States and Norway. M.H. Cullen's co-authors include A.D. Chetiyawardana, Lucinda Billingham, Sally Stenning, C.M. Woodroffe, F. Roila, Francisca M. Marti, A G Stansfeld, Tim Lister, M. John Gill and Igor Novitzky‐Basso and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

M.H. Cullen

60 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M.H. Cullen United Kingdom 23 1.2k 936 933 427 394 61 2.6k
Melvin L. Samuels United States 28 614 0.5× 1.1k 1.2× 1.5k 1.6× 483 1.1× 313 0.8× 44 2.5k
Maike de Wit Germany 26 982 0.8× 1.0k 1.1× 519 0.6× 179 0.4× 476 1.2× 88 2.5k
C B Pratt United States 29 975 0.8× 842 0.9× 384 0.4× 712 1.7× 482 1.2× 65 2.6k
D. Cowen France 28 503 0.4× 916 1.0× 759 0.8× 235 0.6× 184 0.5× 75 2.3k
Julia Meißner Germany 26 676 0.6× 328 0.4× 344 0.4× 173 0.4× 298 0.8× 72 2.5k
Stanislaw Garwicz Sweden 31 539 0.4× 395 0.4× 230 0.2× 560 1.3× 322 0.8× 94 3.0k
Leo Mascarenhas United States 28 966 0.8× 1.3k 1.4× 477 0.5× 792 1.9× 452 1.1× 149 3.1k
Andreas Schuck Germany 25 446 0.4× 1.8k 1.9× 615 0.7× 458 1.1× 250 0.6× 63 2.7k
Donald C. Doll United States 18 827 0.7× 303 0.3× 329 0.4× 247 0.6× 115 0.3× 72 1.8k
Piotr Czauderna Poland 30 1.4k 1.2× 536 0.6× 1.8k 2.0× 910 2.1× 433 1.1× 108 4.1k

Countries citing papers authored by M.H. Cullen

Since Specialization
Citations

This map shows the geographic impact of M.H. Cullen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.H. Cullen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.H. Cullen more than expected).

Fields of papers citing papers by M.H. Cullen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.H. Cullen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.H. Cullen. The network helps show where M.H. Cullen may publish in the future.

Co-authorship network of co-authors of M.H. Cullen

This figure shows the co-authorship network connecting the top 25 collaborators of M.H. Cullen. A scholar is included among the top collaborators of M.H. Cullen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.H. Cullen. M.H. Cullen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oldenburg, Jan, Jorge Aparicio, J. Beyer, et al.. (2014). Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Annals of Oncology. 26(5). 833–838. 45 indexed citations
2.
Cullen, M.H. & Shobhit Baijal. (2009). Prevention of febrile neutropenia: use of prophylactic antibiotics. British Journal of Cancer. 101(S1). S11–S14. 53 indexed citations
3.
Marti, Francisca M., M.H. Cullen, & F. Roila. (2009). Management of febrile neutropenia: ESMO Clinical Recommendations. Annals of Oncology. 20. iv166–iv169. 25 indexed citations
4.
Cullen, M.H., Petr Zatloukal, S Sörenson, et al.. (2008). A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Annals of Oncology. 19(5). 939–945. 64 indexed citations
5.
Cullen, M.H.. (2005). The development of gemcitabine and carboplatin in the treatment of non-small-cell lung cancer. Lung Cancer. 50. S5–S7. 11 indexed citations
6.
Keane, Joseph, et al.. (2004). Tuberculous thyroiditis - a rare cause of hyperthyroidism. 7. 1 indexed citations
7.
8.
Billingham, Lucinda & M.H. Cullen. (2001). The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. Annals of Oncology. 12(12). 1671–1675. 71 indexed citations
9.
Fosså, Sophie D., Sally Stenning, A. Gerl, et al.. (1999). Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. British Journal of Cancer. 80(9). 1392–1399. 89 indexed citations
10.
11.
12.
13.
Klášterský, Jean, M.H. Cullen, David Ball, et al.. (1997). Concurrent treatments and induction treatments for unresectable tumors. Lung Cancer. 17. S27–S28. 2 indexed citations
14.
15.
Cullen, M.H.. (1995). Adjuvant and neo-adjuvant chemotherapy in non-small cell carcinoma. Annals of Oncology. 6. S43–S48. 4 indexed citations
16.
Steyn, Richard, et al.. (1995). Weight gain as an indicator of response to chemotherapy for oesophageal carcinoma. Clinical Oncology. 7(6). 382–384. 11 indexed citations
17.
Allen, Simon, John P. Duffy, Steven J. Walker, et al.. (1994). A phase II study of mitomycin, ifosfamide and cisplatin in operable and inoperable squamous cell carcinoma of the oesophagus. Clinical Oncology. 6(2). 91–95. 11 indexed citations
18.
O’Reilly, Séamus, et al.. (1993). Thyrotoxicosis induced by choriocarcinoma a report of two cases.. PubMed. 86(4). 124, 127–124, 127. 2 indexed citations
19.
Cullen, M.H.. (1989). Optimum Duration of Treatment with Combination Chemotherapy for Small Cell Lung Cancer. CHEST Journal. 96(1). 62S–64S. 1 indexed citations
20.
Cullen, M.H., et al.. (1988). Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare. British Journal of Cancer. 58(3). 359–361. 101 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Melvin L. Samuels Breakdown of academic impact, for papers by Maike de Wit Breakdown of academic impact, for papers by C B Pratt Breakdown of academic impact, for papers by D. Cowen Breakdown of academic impact, for papers by Julia Meißner Breakdown of academic impact, for papers by Stanislaw Garwicz Breakdown of academic impact, for papers by Leo Mascarenhas Breakdown of academic impact, for papers by Andreas Schuck Breakdown of academic impact, for papers by Donald C. Doll Breakdown of academic impact, for papers by Piotr Czauderna
Rankless by CCL
2026